Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.36 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.36 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26636357 | 1.00 | LTA4H (0.43) | LTA4HEPHX2PPARACYP4A11PPARG | |
| SCHEMBL30670073 | 0.96 | CYP4F2 (0.39) | LTA4HEPHX2PPARACYP4A11PPARG | |
| SCHEMBL26619309 | 0.96 | CYP4F2 (0.39) | LTA4HEPHX2PPARACYP4A11PPARG | |
| SCHEMBL26637106 | 0.91 | PTGS2 (0.41) | LTA4HEPHX2PPARACYP4A11PPARG | |
| SCHEMBL30735264 | 0.91 | PTGS2 (0.41) | LTA4HEPHX2PPARACYP4A11PPARG | |
| SCHEMBL26635820 | 0.86 | CYP4F2 (0.43) | PPARACYP4A11PPARGCYP4F2 | |
| SCHEMBL30734465 | 0.86 | CYP4F2 (0.43) | PPARACYP4A11PPARGCYP4F2 | |
| SCHEMBL26635941 | 0.82 | F2 (0.35) | EPHX2PPARAPPARGPPARDF2 | |
| SCHEMBL30734943 | 0.82 | PPARG (0.35) | EPHX2PPARAPPARGPPARDF2 | |
| SCHEMBL26619451 | 0.82 | PPARG (0.35) | EPHX2PPARAPPARGPPARDF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282771-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-11 | — | — | US | disclosed |
| EP-4519272-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4519259-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023215449-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215482-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282771-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2, BCL2L10, BCL2L1 | LTA4H 4194/4885EPHX2 2276/4885PPARA 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.